Jyotsna Fuloria

902 total citations
30 papers, 363 citations indexed

About

Jyotsna Fuloria is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Jyotsna Fuloria has authored 30 papers receiving a total of 363 indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 14 papers in Pulmonary and Respiratory Medicine and 7 papers in Surgery. Recurrent topics in Jyotsna Fuloria's work include Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (4 papers) and HER2/EGFR in Cancer Research (3 papers). Jyotsna Fuloria is often cited by papers focused on Colorectal Cancer Treatments and Studies (6 papers), Cancer Treatment and Pharmacology (4 papers) and HER2/EGFR in Cancer Research (3 papers). Jyotsna Fuloria collaborates with scholars based in United States, India and Switzerland. Jyotsna Fuloria's co-authors include Dinesh Chandra Doval, Sunil K. Gupta, Jagdev Singh Sekhon, Vijay K. Shukla, Sanjay Gupta, Virginia F. Borges, Karen Wang, Mark D. Pegram, Purvish M. Parikh and Charles L. Shapiro and has published in prestigious journals such as Journal of Clinical Oncology, Cancer and British Journal of Cancer.

In The Last Decade

Jyotsna Fuloria

28 papers receiving 351 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jyotsna Fuloria United States 12 172 148 126 75 47 30 363
Yoshio Kadokawa Japan 11 112 0.7× 168 1.1× 185 1.5× 70 0.9× 48 1.0× 34 433
Chunfang Gao China 11 196 1.1× 315 2.1× 64 0.5× 106 1.4× 41 0.9× 19 469
Madhavan V. Pillai United States 7 419 2.4× 108 0.7× 133 1.1× 59 0.8× 49 1.0× 15 512
Aya Sugimoto Japan 14 146 0.8× 102 0.7× 127 1.0× 113 1.5× 41 0.9× 46 411
Masahiro Shinoda Japan 12 162 0.9× 167 1.1× 72 0.6× 53 0.7× 87 1.9× 45 359
P. Flemming Germany 12 169 1.0× 148 1.0× 131 1.0× 69 0.9× 56 1.2× 30 466
Priyanka Pathak United States 8 206 1.2× 155 1.0× 96 0.8× 45 0.6× 187 4.0× 23 425
Sanders Chang United States 11 114 0.7× 109 0.7× 74 0.6× 138 1.8× 62 1.3× 25 417
Marc I. Brand United States 16 309 1.8× 347 2.3× 61 0.5× 74 1.0× 53 1.1× 37 594
Hideki Ura Japan 14 247 1.4× 266 1.8× 131 1.0× 130 1.7× 32 0.7× 42 588

Countries citing papers authored by Jyotsna Fuloria

Since Specialization
Citations

This map shows the geographic impact of Jyotsna Fuloria's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jyotsna Fuloria with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jyotsna Fuloria more than expected).

Fields of papers citing papers by Jyotsna Fuloria

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jyotsna Fuloria. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jyotsna Fuloria. The network helps show where Jyotsna Fuloria may publish in the future.

Co-authorship network of co-authors of Jyotsna Fuloria

This figure shows the co-authorship network connecting the top 25 collaborators of Jyotsna Fuloria. A scholar is included among the top collaborators of Jyotsna Fuloria based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jyotsna Fuloria. Jyotsna Fuloria is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Sabino‐Santos, Gilberto, Sam Litwin, Debra Elliott, et al.. (2024). Post‐COVID immunity in patients with solid tumor or hematological malignancies treated with SARS‐CoV‐2 monoclonal antibodies. Immunity Inflammation and Disease. 12(12). e70039–e70039. 1 indexed citations
2.
Wu, Jiande, et al.. (2022). Landscape of Molecular Crosstalk Perturbation between Lung Cancer and COVID-19. International Journal of Environmental Research and Public Health. 19(6). 3454–3454. 2 indexed citations
3.
Perry, Laura M., Oliver Sartor, Sarah Alonzi, et al.. (2021). Increasing Readiness for Early Integrated Palliative Oncology Care: Development and Initial Evaluation of the EMPOWER 2 Intervention. Journal of Pain and Symptom Management. 62(5). 987–996. 15 indexed citations
4.
Kao, Yu-Hsiang, Tung‐Sung Tseng, Jennifer Hart, et al.. (2021). Association Between the 5As and Stage of Change Among African American Smokers Eligible for Low-Dose Computed Tomography Screening. Preventing Chronic Disease. 18. E71–E71.
5.
Lasky, Joseph A., Jyotsna Fuloria, Marion E. Morrison, et al.. (2020). Design and Rationale of a Randomized, Double-Blind, Placebo-Controlled, Phase 2/3 Study Evaluating Dociparstat in Acute Lung Injury Associated with Severe COVID-19. Advances in Therapy. 38(1). 782–791. 13 indexed citations
6.
Tseng, Tung‐Sung, et al.. (2019). Knowledge and attitudes towards low dose computed tomography lung cancer screening and smoking among African Americans—a mixed method study. Translational Cancer Research. 8(4). 2 indexed citations
7.
Tseng, Tung‐Sung, et al.. (2019). Knowledge and attitudes towards low dose computed tomography lung cancer screening and smoking among African Americans—a mixed method study. Translational Cancer Research. 8(S4). S431–S442. 13 indexed citations
8.
Verma, Udit, Yull Arriaga, Heinz‐Josef Lenz, et al.. (2016). Regorafenib for previously treated metastatic colorectal cancer (mCRC): A subgroup analysis of 364 patients in the USA treated in the international, open-label phase IIIb CONSIGN study.. Journal of Clinical Oncology. 34(4_suppl). 735–735. 1 indexed citations
9.
Nemenqani, Dalal, et al.. (2015). Gallbladder Neuroendocrine Neoplasms: A Case Report of Gallbladder Small Cell Carcinoma. Journal of Gastrointestinal Cancer. 47(4). 432–435. 6 indexed citations
10.
Dornelles, Adriana, et al.. (2014). Outcomes of neoadjuvant chemotherapy with FOLFOX/FOLFIRINOX and chemoradiotherapy in borderline resectable pancreatic cancer: Single-institution experience.. Journal of Clinical Oncology. 32(3_suppl). 327–327. 1 indexed citations
11.
12.
Fuloria, Jyotsna. (2012). Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer. OncoTargets and Therapy. 5. 133–133. 11 indexed citations
13.
Bolton, John S., Michael J. O’Connell, Michelle R. Mahoney, et al.. (2011). Hepatic Arterial Infusion and Systemic Chemotherapy After Multiple Metastasectomy in Patients With Colorectal Carcinoma Metastatic to the Liver: A North Central Cancer Treatment Group (NCCTG) Phase II Study, 92-46-52. Clinical Colorectal Cancer. 11(1). 31–37. 15 indexed citations
14.
Khan, Nisar, William Conway, & Jyotsna Fuloria. (2011). A single-center experience of small-bowel adenocarcinomas.. Journal of Clinical Oncology. 29(4_suppl). 337–337. 1 indexed citations
15.
Pegram, Mark D., Virginia F. Borges, Nuhad K. Ibrahim, et al.. (2009). Phase I dose escalation pharmacokinetic assessment of intravenous humanized anti-MUC1 antibody AS1402 in patients with advanced breast cancer. Breast Cancer Research. 11(5). R73–R73. 37 indexed citations
16.
Quinn, David I., John Nemunaitis, Jyotsna Fuloria, et al.. (2009). Effect of the Cytochrome P450 2C19 Inhibitor Omeprazole on the Pharmacokinetics and Safety Profile of Bortezomib in Patients with Advanced Solid Tumours, Non-Hodgkinʼs Lymphoma or Multiple Myeloma. Clinical Pharmacokinetics. 48(3). 199–209. 30 indexed citations
17.
Kearns, Ann E., Donald W. Northfelt, Amylou C. Dueck, et al.. (2009). Osteoporosis prevention in prostate cancer patients receiving androgen ablation therapy: placebo-controlled double-blind study of estradiol and risedronate: N01C8. Supportive Care in Cancer. 18(3). 321–328. 19 indexed citations
18.
Garrison, L., J Cassidy, MN Saleh, et al.. (2007). Cost comparison of XELOX compared to FOLFOX4 with or without bevacizumab (bev) in metastatic colorectal cancer. Journal of Clinical Oncology. 25(18_suppl). 4074–4074. 14 indexed citations
19.
Gupta, Sumit, et al.. (2005). A multicenter phase II study of gemcitabine, paclitaxel, and cisplatin in chemonaïve advanced ovarian cancer. Gynecologic Oncology. 98(1). 134–140. 6 indexed citations
20.
Doval, Dinesh Chandra, Jagdev Singh Sekhon, Sunil K. Gupta, et al.. (2004). A Phase II study of gemcitabine and cisplatin in chemotherapy-naive, unresectable gall bladder cancer. British Journal of Cancer. 90(8). 1516–1520. 104 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Yoshio Kadokawa Breakdown of academic impact, for papers by Chunfang Gao Breakdown of academic impact, for papers by Madhavan V. Pillai Breakdown of academic impact, for papers by Aya Sugimoto Breakdown of academic impact, for papers by Masahiro Shinoda Breakdown of academic impact, for papers by P. Flemming Breakdown of academic impact, for papers by Priyanka Pathak Breakdown of academic impact, for papers by Sanders Chang Breakdown of academic impact, for papers by Marc I. Brand Breakdown of academic impact, for papers by Hideki Ura
Rankless by CCL
2026